In addition, recently proposed STING immune agonist SR717 has been employed to stimulate the anti‐tumor immunoresponses via promoting CD8+ T cells and nature killer cells (NKs) maturation and cytokine secretion, enabling the sonoimmunotherapy (SIT). Here, CD8A is linked to neoplasm.